Cargando…
Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
BACKGROUND: Doxorubicin (Dox) is widely used to treat progressed bladder cancer after transurethral resection. The use of Dox-chemotherapy has been limited due to induced drug resistance and cumulative cardiotoxic effects. N-benzyladriamycin-14-valerate (AD198), a novel derivative of Dox, has a pote...
Autores principales: | Smolensky, Dmitriy, Rathore, Kusum, Cekanova, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657321/ https://www.ncbi.nlm.nih.gov/pubmed/26597249 http://dx.doi.org/10.1186/s12885-015-1930-5 |
Ejemplares similares
-
A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
por: Rathore, Kusum, et al.
Publicado: (2015) -
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer
por: Smolensky, Dmitriy, et al.
Publicado: (2016) -
Animal model of naturally occurring bladder cancer: Characterization of four new canine transitional cell carcinoma cell lines
por: Rathore, Kusum, et al.
Publicado: (2014) -
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
por: Bourn, Jennifer, et al.
Publicado: (2018) -
Animal models and therapeutic molecular targets of cancer: utility and limitations
por: Cekanova, Maria, et al.
Publicado: (2014)